Gleiss Lutz advises Roche on its acquisition of the TIB Molbiol Group
A Gleiss Lutz team has advised the global pharmaceutical and diagnostics group Roche on its acquisition of all shares in the Berlin-based TIB Molbiol Group, an expert in molecular diagnostics. The transaction is subject to the customary conditions and is expected to close in the fourth quarter of 2021. The acquisition will expand Roche’s broad portfolio in molecular diagnostic solutions with a wide range of assays for infectious diseases, such as SARS-CoV-2 variants.
Roche is a global company specialising in the research and development of medicines and diagnostics. It is also the world's largest biotech company with medicines for oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Founded in 1896 and headquartered in Basel, Switzerland, the Roche Group operates in over 100 countries and employs approximately 100,000 people worldwide in 2020. In 2020, Roche invested CHF 12.2 billion in research and development and achieved sales of CHF 58.3 billion.
The biotechnology company TIB Molbiol was founded in 1990 and has been supplying the international market with diagnostic and research reagents ever since. As a manufacturer of customised oligonucleotides, the company is a partner in the development of molecular diagnostics and has a broad portfolio of diagnostic assays. The company, with registered office in Berlin, has locations in the U.S., Colombia, Italy, Spain and Australia.
Dr Ruben Perren und Dr Felix Kobel from Roche’s legal department acted as lead counsel on the transaction.
The following Gleiss Lutz team advised Roche on the transaction: Dr Alexander Schwarz (partner, Düsseldorf), Dr Martin Viciano Gofferje (partner, Berlin, both lead), Dr Fabian Mumme (Düsseldorf), Dr Christoph Meissner (Berlin), Friedrich Baumgärtel, Kai Zimutta (both Düsseldorf, all M&A), Dr Alexander Molle (partner), Jan Hinrichs, Dr Felix Müller (all IP/IT), Dr Enno Burk (counsel, Healthcare, all Berlin), Dr Johann Wagner (partner, Tax, Hamburg), Dr Jacob von Andreae (partner), Aylin Hoffs, Matthias Hahn, Lennart Förster (all Public Business Law, Düsseldorf), Dr Ingo Brinker (partner), Dr Iris Benedikt-Buckenleib (counsel, both Competition/Antitrust, Munich), Dr Stefan Lingemann (partner), Josefine Chakrabarti (both Berlin), Dr Simona Kreis (Hamburg, all Employment), Konrad Discher (counsel, Real Estate, Frankfurt).
Gleiss Lutz has advised Roche on several transactions in the past, including the sale of Roche Diagnostics IT Solutions and Nexus.